Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia

Srdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, Jorge Cortes, Francis J. Giles, Anna Rogers, Maher Albitar

Research output: Contribution to journalArticle

Abstract

The impact of elevated vascular endothelial growth factor (VEGF) expression on the course of chronic myeloid leukemia (CML) is unknown. By radioimmunoassay, we measured pretreatment cellular VEGF protein in bone marrow samples from 184 (148 chronic and 36 accelerated/blastic phases) CML patients and found the levels to be 1.6-fold higher than in 31 normal control bone marrow samples (P = .000 01). No significant differences were found in VEGF levels by different phases of CML (P = .1). VEGF levels correlated with older age (P = .01) and higher platelet count (P = .0003), but also with smaller spleen size (P = .004), lower white blood cell count (P = .0006), and lower percentage of peripheral blasts (P = .04). With the use of Cox proportional hazard model and VEGF levels as a continuous variable, high VEGF levels correlated with shorter survival of patients in chronic CML (P = .008). Multivariate analysis showed that VEGF was not independent of the synthesis stage (P = .09). These data suggest that VEGF plays a role in the biology of CML and that VEGF inhibitors should be investigated in CML.

Original languageEnglish (US)
Pages (from-to)2265-2267
Number of pages3
JournalBlood
Volume99
Issue number6
DOIs
StatePublished - Mar 15 2002
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Vascular Endothelial Growth Factor A
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Accelerated Phase
Bone
Bone Marrow
Platelets
Platelet Count
Leukocyte Count
Proportional Hazards Models
Radioimmunoassay
Hazards
Blood
Spleen
Multivariate Analysis
Cells

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. / Verstovsek, Srdan; Kantarjian, Hagop; Manshouri, Taghi; Cortes, Jorge; Giles, Francis J.; Rogers, Anna; Albitar, Maher.

In: Blood, Vol. 99, No. 6, 15.03.2002, p. 2265-2267.

Research output: Contribution to journalArticle

Verstovsek, S, Kantarjian, H, Manshouri, T, Cortes, J, Giles, FJ, Rogers, A & Albitar, M 2002, 'Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia', Blood, vol. 99, no. 6, pp. 2265-2267. https://doi.org/10.1182/blood.V99.6.2265
Verstovsek, Srdan ; Kantarjian, Hagop ; Manshouri, Taghi ; Cortes, Jorge ; Giles, Francis J. ; Rogers, Anna ; Albitar, Maher. / Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. In: Blood. 2002 ; Vol. 99, No. 6. pp. 2265-2267.
@article{9cb5128902654c4b811efbbb4e474d67,
title = "Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia",
abstract = "The impact of elevated vascular endothelial growth factor (VEGF) expression on the course of chronic myeloid leukemia (CML) is unknown. By radioimmunoassay, we measured pretreatment cellular VEGF protein in bone marrow samples from 184 (148 chronic and 36 accelerated/blastic phases) CML patients and found the levels to be 1.6-fold higher than in 31 normal control bone marrow samples (P = .000 01). No significant differences were found in VEGF levels by different phases of CML (P = .1). VEGF levels correlated with older age (P = .01) and higher platelet count (P = .0003), but also with smaller spleen size (P = .004), lower white blood cell count (P = .0006), and lower percentage of peripheral blasts (P = .04). With the use of Cox proportional hazard model and VEGF levels as a continuous variable, high VEGF levels correlated with shorter survival of patients in chronic CML (P = .008). Multivariate analysis showed that VEGF was not independent of the synthesis stage (P = .09). These data suggest that VEGF plays a role in the biology of CML and that VEGF inhibitors should be investigated in CML.",
author = "Srdan Verstovsek and Hagop Kantarjian and Taghi Manshouri and Jorge Cortes and Giles, {Francis J.} and Anna Rogers and Maher Albitar",
year = "2002",
month = "3",
day = "15",
doi = "10.1182/blood.V99.6.2265",
language = "English (US)",
volume = "99",
pages = "2265--2267",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia

AU - Verstovsek, Srdan

AU - Kantarjian, Hagop

AU - Manshouri, Taghi

AU - Cortes, Jorge

AU - Giles, Francis J.

AU - Rogers, Anna

AU - Albitar, Maher

PY - 2002/3/15

Y1 - 2002/3/15

N2 - The impact of elevated vascular endothelial growth factor (VEGF) expression on the course of chronic myeloid leukemia (CML) is unknown. By radioimmunoassay, we measured pretreatment cellular VEGF protein in bone marrow samples from 184 (148 chronic and 36 accelerated/blastic phases) CML patients and found the levels to be 1.6-fold higher than in 31 normal control bone marrow samples (P = .000 01). No significant differences were found in VEGF levels by different phases of CML (P = .1). VEGF levels correlated with older age (P = .01) and higher platelet count (P = .0003), but also with smaller spleen size (P = .004), lower white blood cell count (P = .0006), and lower percentage of peripheral blasts (P = .04). With the use of Cox proportional hazard model and VEGF levels as a continuous variable, high VEGF levels correlated with shorter survival of patients in chronic CML (P = .008). Multivariate analysis showed that VEGF was not independent of the synthesis stage (P = .09). These data suggest that VEGF plays a role in the biology of CML and that VEGF inhibitors should be investigated in CML.

AB - The impact of elevated vascular endothelial growth factor (VEGF) expression on the course of chronic myeloid leukemia (CML) is unknown. By radioimmunoassay, we measured pretreatment cellular VEGF protein in bone marrow samples from 184 (148 chronic and 36 accelerated/blastic phases) CML patients and found the levels to be 1.6-fold higher than in 31 normal control bone marrow samples (P = .000 01). No significant differences were found in VEGF levels by different phases of CML (P = .1). VEGF levels correlated with older age (P = .01) and higher platelet count (P = .0003), but also with smaller spleen size (P = .004), lower white blood cell count (P = .0006), and lower percentage of peripheral blasts (P = .04). With the use of Cox proportional hazard model and VEGF levels as a continuous variable, high VEGF levels correlated with shorter survival of patients in chronic CML (P = .008). Multivariate analysis showed that VEGF was not independent of the synthesis stage (P = .09). These data suggest that VEGF plays a role in the biology of CML and that VEGF inhibitors should be investigated in CML.

UR - http://www.scopus.com/inward/record.url?scp=0037085781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037085781&partnerID=8YFLogxK

U2 - 10.1182/blood.V99.6.2265

DO - 10.1182/blood.V99.6.2265

M3 - Article

C2 - 11877311

AN - SCOPUS:0037085781

VL - 99

SP - 2265

EP - 2267

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -